SAMHSA's Oversight of Accreditation Bodies for Opioid Treatment Programs
The Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that 2.5 million people have an opioid use disorder related to prescription pain relievers and/or heroin. Medication-Assisted Treatment (MAT), provided by opioid treatment programs (OTPs), is a significant component of the treatment protocols for opioid use disorder and plays a large role in combating the opioid epidemic in the United States. SAMHSA issued final regulations to establish an oversight system for the treatment of substance use disorders with MAT. These regulations (42 CFR Part 8) established procedures for an entity to become an approved accreditation body, which evaluates OTPs and ensures SAMHSA's opioid dependency treatment standards are met. Our objective is to determine whether SAMHSA's oversight of accreditation bodies complied with Federal requirements. This series of audits will include SAMHSA-approved accrediting bodies that have accredited OTPs.
|Announced or Revised||Agency||Title||Component||Report Number(s)||Expected Issue Date (FY)|
|July 2018||Substance Abuse and Mental Health Services Administration||SAMHSA's Oversight of Accreditation Bodies for Opioid Treatment Programs||Office of Audit Services||W-00-18-59035||2020|